BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tao L, Mu X, Chen H, Jin D, Zhang R, Zhao Y, Fan J, Cao M, Zhou Z. FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med 2021;11:e310. [PMID: 33634966 DOI: 10.1002/ctm2.310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Zhang S, Bai Y, Li G, Wang S, Chen J, Liu X, Yin H. Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma. Front Cell Dev Biol 2022;10:809747. [PMID: 35309945 DOI: 10.3389/fcell.2022.809747] [Reference Citation Analysis]
2 Li A, Gan Y, Cao C, Ma B, Zhang Q, Zhang Q, Yao L. Transcriptome-Wide Map of N6-Methyladenosine Methylome Profiling in Human Bladder Cancer. Front Oncol 2021;11:717622. [PMID: 34868913 DOI: 10.3389/fonc.2021.717622] [Reference Citation Analysis]
3 Zhou G, Yan K, Liu J, Gao L, Jiang X, Fan Y. FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner. Cell Death Discov 2021;7:329. [PMID: 34725345 DOI: 10.1038/s41420-021-00724-5] [Reference Citation Analysis]
4 Lian Z, Yan X, Diao Y, Cui D, Liu H. T cell differentiation protein 2 facilitates cell proliferation by enhancing mTOR-mediated ribosome biogenesis in non-small cell lung cancer. Discov Oncol 2022;13:26. [PMID: 35437691 DOI: 10.1007/s12672-022-00488-z] [Reference Citation Analysis]
5 Zhuo Z, Hua RX, Zhang H, Lin H, Fu W, Zhu J, Cheng J, Zhang J, Li S, Zhou H, Xia H, Liu G, Jia W, He J. METTL14 gene polymorphisms decrease Wilms tumor susceptibility in Chinese children. BMC Cancer 2021;21:1294. [PMID: 34863142 DOI: 10.1186/s12885-021-09019-5] [Reference Citation Analysis]
6 Sun J, Ma X, Ying Y, Wang W, Shen H, Wang S, Xie H, Yi J, Zhan W, Li J, Liu B. SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer. Cell Death Discov 2022;8:199. [PMID: 35418191 DOI: 10.1038/s41420-022-01010-8] [Reference Citation Analysis]
7 Chen DH, Zhang JG, Wu CX, Li Q. Non-Coding RNA m6A Modification in Cancer: Mechanisms and Therapeutic Targets. Front Cell Dev Biol 2021;9:778582. [PMID: 35004679 DOI: 10.3389/fcell.2021.778582] [Reference Citation Analysis]
8 Cui Y, Zhang C, Ma S, Li Z, Wang W, Li Y, Ma Y, Fang J, Wang Y, Cao W, Guan F. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2021;40:294. [PMID: 34544449 DOI: 10.1186/s13046-021-02096-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li Y, Su R, Deng X, Chen Y, Chen J. FTO in cancer: functions, molecular mechanisms, and therapeutic implications. Trends Cancer 2022:S2405-8033(22)00054-1. [PMID: 35346615 DOI: 10.1016/j.trecan.2022.02.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yuan C, Zhang J, Deng C, Xia Y, Li B, Meng S, Jin X, Cheng L, Li H, Zhang C, He Y. Crosstalk of Histone and RNA Modifications Identified a Stromal-Activated Subtype with Poor Survival and Resistance to Immunotherapy in Gastric Cancer. Front Pharmacol 2022;13:868830. [DOI: 10.3389/fphar.2022.868830] [Reference Citation Analysis]
11 Huang S, Lyu S, Gao Z, Zha W, Wang P, Shan Y, He J, Li Y. m6A-Related lncRNAs Are Potential Biomarkers for the Prognosis of Metastatic Skin Cutaneous Melanoma. Front Mol Biosci 2021;8:687760. [PMID: 34026852 DOI: 10.3389/fmolb.2021.687760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yu Q, Zhu H, Wang H, Aimaier R, Chung M, Wang Z, Li Q, Falzone L. M6A-Related Bioinformatics Analysis Reveals a New Prognostic Risk Signature in Cutaneous Malignant Melanoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/8114731] [Reference Citation Analysis]
13 Chen H, Jia B, Zhang Q, Zhang Y. Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. Front Oncol 2022;12:870636. [PMID: 35530301 DOI: 10.3389/fonc.2022.870636] [Reference Citation Analysis]
14 Yi W, Yu Y, Li Y, Yang J, Gao S, Xu L. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients. Bioengineered 2021;12:5323-33. [PMID: 34499008 DOI: 10.1080/21655979.2021.1964893] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhao J, Lin X, Zhuang J, He F. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Front Genet 2021;12:714697. [PMID: 34777460 DOI: 10.3389/fgene.2021.714697] [Reference Citation Analysis]
16 Wang Y, Li M, Zhang L, Chen Y, Zhang S. m6A demethylase FTO induces NELL2 expression by inhibiting E2F1 m6A modification leading to metastasis of non-small cell lung cancer. Mol Ther Oncolytics 2021;21:367-76. [PMID: 34169146 DOI: 10.1016/j.omto.2021.04.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ji F, Fu X, Li G, He Q, Qiu X. FTO Prevents Thyroid Cancer Progression by SLC7A11 m6A Methylation in a Ferroptosis-Dependent Manner. Front Endocrinol 2022;13:857765. [DOI: 10.3389/fendo.2022.857765] [Reference Citation Analysis]
18 You Y, Fu Y, Huang M, Shen D, Zhao B, Liu H, Zheng Y, Huang L. Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases. IJMS 2022;23:5815. [DOI: 10.3390/ijms23105815] [Reference Citation Analysis]
19 Zheng B, Wang J, Zhao G, Chen X, Yao Z, Niu Z, He W. A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder. Biosci Rep 2021;41:BSR20204456. [PMID: 33779704 DOI: 10.1042/BSR20204456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Guimarães-Teixeira C, Barros-Silva D, Lobo J, Soares-Fernandes D, Constâncio V, Leite-Silva P, Silva-Santos R, Braga I, Henrique R, Miranda-Gonçalves V, Jerónimo C. Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. J Pers Med 2021;11:996. [PMID: 34683137 DOI: 10.3390/jpm11100996] [Reference Citation Analysis]
21 Zhao C, Liu Y, Ju S, Wang X. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker. Int J Gen Med 2021;14:7411-22. [PMID: 34744452 DOI: 10.2147/IJGM.S331752] [Reference Citation Analysis]
22 Liu Q. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. Front Genet 2021;12:825109. [PMID: 35087575 DOI: 10.3389/fgene.2021.825109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Pan J, Liu F, Xiao X, Xu R, Dai L, Zhu M, Xu H, Xu Y, Zhao A, Zhou W, Dang Y, Ji G. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis. J Exp Clin Cancer Res 2022;41:19. [PMID: 35012593 DOI: 10.1186/s13046-021-02227-8] [Reference Citation Analysis]
24 Jiang Z, Zhang Y, Chen K, Yang X, Liu J. Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer. Int J Gen Med 2021;14:5017-28. [PMID: 34511985 DOI: 10.2147/IJGM.S327765] [Reference Citation Analysis]